Replies to post #1225 on Armata Pharmaceuticals, Inc. (ARMP)

[timberwolf7]

1. Why can't an 'adjustment be sustained BELOW the current market value'? It does a 1-4 to get the share price to $1.30 or so based on todays price. Whats to stop the market from pricing it at a $ after the split?
Sure, somewhere down the road, say after a ph 1/2 is finally completed, the market likes what it sees and says, ok, $2/sh.. But with nothing to sell but an 'idea' and some initial results from the expanded access program??
My reason for being cautious is, sometimes we try to apply valuations to something that has nothing more than an idea as if the idea is close to becoming reality...

So I don't own any, and I don't intend to until after the r/split takes place, and the market puts a new price on the shares.. and have to say, so far, the market doesn't seem to be very impressed with the merger news

To me, there is a time to trade it (have done so since the 20 cent area) and then there MIGHT be a time to buy and hold it.. Guess we will find out post the merger and IF they do the split, what price the market gives them vs what we think its worth..

Good luck... but have to admit, I really like what they are doing from a product development aspect.

[gimmeshelter]

And that doesn't factor in the imminent grant that CEO Grint alluded to in the last CC, or the C3J "big pharma" deal that will be announced at the merger closing. This may be a rocket ship in the next few weeks.